Akebia shareholders elect three directors, approve 2023 stock plan at annual meeting

Akebia Therapeutics, Inc.

Class III directors Adrian Adams, Michael Rogers, LeAnne M. Zumwalt elected for three-year terms.
2023 Stock Incentive Plan approved: 61.2M for, 22.8M against, 508K abstentions.
Non-binding advisory vote on executive compensation passed: 59.7M for, 24.2M against.
Ernst & Young LLP ratified as auditor for FY2023: 116.5M for, 5.2M against.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-12-31 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-12-31

Exact text from the filing

(iii) The proposal to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 received the following votes: Votes For: 116,535,030 Votes Against: 5,158,525 Abstentions: 1,383,705

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders approved Election of three Class III directors to serve until the 2026 annual meeting.

Proposal: director election
Outcome: passed

Exact text from the filing

The Class III directors elected to the Board, as well as the number of votes for, votes withheld and broker non-votes with respect to each of these individuals, are set forth below: Director Votes For Votes Withheld Broker Non-Votes Adrian Adams 61,064,658 23,449,941 38,562,661 Michael Rogers 64,246,561 20,268,038 38,562,661 LeAnne M. Zumwalt 60,778,528 23,736,071 38,562,661

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders approved Approval of the 2023 Equity Incentive Plan.

Proposal: equity plan
Outcome: passed

Exact text from the filing

(ii) The proposal to approve the 2023 Plan received the following votes: Votes For: 61,173,115 Votes Against: 22,833,112 Abstentions: 508,372 Broker Non-Votes 38,562,661

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Akebia Therapeutics, Inc. shareholders approved Advisory vote on executive compensation.

Proposal: say on pay
Outcome: passed

Exact text from the filing

(iii) The advisory vote on the compensation of the Company’s named executive officers received the following votes: Votes For: 59,695,038 Votes Against: 24,230,548 Abstentions: 589,013 Broker Non-Votes 38,562,661

View on SEC.gov

Browse all shareholder votes →

Akebia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001517022-23-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.